Aromatase Inhibitors Treatment Alone or With GH Increases Final Height in Short-statured Pubertal Boys—Real-world Data
The Journal of Clinical Endocrinology & Metabolism · 18.11.2025 · 110 (12) · e4129-e4136
DOI: 10.1210/clinem/dgaf224 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 07.04.2025. Verfasst von Michal Yackobovitch-Gavan und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center…. Hauptthemen laut MEDLINE: Body Height, Aromatase Inhibitors, Growth Disorders, Human Growth Hormone. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Context
Short-statured midpubertal boys with predicted adult height (PAHt) below the third percentile are a therapeutic challenge. Aromatase inhibitors (AI) delay estrogen-driven epiphyseal fusion and possibly enhance adult height (AHt).
Objective
To assess the efficacy of AI treatment on AHt in midpubertal boys with a short PAHt due to advanced bone age (BA) or idiopathic short stature (ISS).
Design
Retrospective study.
Setting
Tertiary pediatric endocrine referral center. Patients and Methods Two groups of midpubertal boys treated with AI were studied: 27 boys with fast puberty compared to matched untreated controls and 16 boys with ISS treated with GH and AI (GH&AI) compared to those treated with GH only. Anthropometric measurements, BA and PAHt, were tracked. AHt was compared across groups. Main Outcome Measures Achieved AHt in AI-treated boys vs controls and the PAHt.
Results
The median duration of AI treatment was 2.8 years for the AI-only group and 2 years for the GH&AI group. Throughout treatment, AI-treated groups gained height similarly to controls and showed a decrease in BA SD score (AI only: P = .009; GH&AI: P = .029) and an improvement in PAHt (AI only: P = .003; GH&AI: P = .037). Compared to controls, AI-treated children achieved greater AHt (AI only: 166.6 ± 3.1 cm vs 163.4 ± 1.3 cm, P = .003; GH&AI: 167.3 ± 6.1 cm vs 164.9 ± 3.5 cm, P = .194). The difference between AHt and PAHt at baseline was more pronounced in the AI-treated groups (AI only: 3.8 ± 3.5 cm vs −0.3 ± 5.0 cm, P = .001; GH&AI: 7.5 ± 5.2 cm vs 4.3 ± 3.6 cm, P = .050).
Conclusion
AI treatment extends the growth period, resulting in an AHt surpassing initial predictions. Our findings underscore the potential of AI treatment in midpubertal boys with a short PAHt due to advanced BA and in those treated with GH for ISS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petach Tikva 49202, Israel.
- Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
ORCID-Profile: Moshe Phillip, Tal Oron
Zitieren
APA
Yackobovitch-Gavan, M., Tenenbaum, A., Phillip, M., Lazar, L., & Oron, T. (2025). Aromatase Inhibitors Treatment Alone or With GH Increases Final Height in Short-statured Pubertal Boys—Real-world Data. The Journal of Clinical Endocrinology & Metabolism, 110(12), e4129-e4136. https://doi.org/10.1210/clinem/dgaf224
Vancouver
Yackobovitch-Gavan M, Tenenbaum A, Phillip M, Lazar L, Oron T. Aromatase Inhibitors Treatment Alone or With GH Increases Final Height in Short-statured Pubertal Boys—Real-world Data. The Journal of Clinical Endocrinology & Metabolism. 2025;110(12):e4129-e4136. doi:10.1210/clinem/dgaf224
BibTeX
@article{YackobovitchGavan2025,
author = {Yackobovitch-Gavan, Michal and Tenenbaum, Ariel and Phillip, Moshe and Lazar, Liora and Oron, Tal},
title = {Aromatase Inhibitors Treatment Alone or With GH Increases Final Height in Short-statured Pubertal Boys—Real-world Data},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {12},
pages = {e4129--e4136},
doi = {10.1210/clinem/dgaf224}
}
EUVIMED